JPMorgan Chase & Co. Takes $871,000 Position in Septerna, Inc. (NASDAQ:SEPN)

JPMorgan Chase & Co. bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 38,015 shares of the company's stock, valued at approximately $871,000. JPMorgan Chase & Co. owned 0.09% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of SEPN. Vanguard Group Inc. bought a new position in Septerna during the 4th quarter worth about $22,557,000. Charles Schwab Investment Management Inc. bought a new position in shares of Septerna during the fourth quarter valued at approximately $3,197,000. Bank of New York Mellon Corp purchased a new position in Septerna during the fourth quarter valued at approximately $872,000. Lindbrook Capital LLC bought a new position in Septerna in the fourth quarter worth approximately $481,000. Finally, Rhumbline Advisers purchased a new stake in Septerna during the fourth quarter worth $458,000.

Septerna Trading Up 4.8 %

Shares of SEPN traded up $0.34 during midday trading on Friday, hitting $7.48. 202,765 shares of the company's stock traded hands, compared to its average volume of 420,448. Septerna, Inc. has a 1 year low of $4.17 and a 1 year high of $28.99. The company's fifty day moving average is $6.10.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million during the quarter, compared to analysts' expectations of $0.13 million. As a group, research analysts forecast that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Buying and Selling

In related news, Director Alan Ezekowitz acquired 41,355 shares of the stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the purchase, the director now owns 104,101 shares of the company's stock, valued at approximately $624,606. This represents a 65.91 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gil M. Labrucherie acquired 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $175,500. The trade was a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 74,346 shares of company stock worth $439,670 in the last three months.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SEPN. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th. Wells Fargo & Company decreased their price target on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research report on Friday, March 28th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.